ASCO 2020: Researchers underscore efficacy of pembrolizumab plus

Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti

PDF) Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways, Cancer Cell International

ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma - ecancer

Frontiers Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China

IJMS, Free Full-Text

Frontiers Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

PDF) Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Immunotherapy: combination regimens and new data on the significance of mutations - memoinOncology

Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases

Immune-based therapies in penile cancer

Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023)

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

PDF) Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis

Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook, Molecular Cancer